Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3
Reich, Kristian (Translational Research in Inflammatory Skin Diseases. Institute for Health Services Research in Dermatology and Nursing. University Medical Center Hamburg-Eppendorf)
Hansen, Jes Birger (LEO Pharma)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Konstantinou, M.P. (Service de Dermatologie. Larrey Hospital)
Warren, R. B. (Dermatology Centre. Salford Royal NHS Foundation Trust. Manchester NIHR Biomedical Research Centre. University of Manchester)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Background: The pathway for treatment of psoriasis is partly dependent upon disease severity, and patients may experience inadequate response at any point along the treatment pathway. Patients who repeatedly fail therapy represent a population in whom effective and well-tolerated treatment options are limited. Objectives: To investigate and describe patients achieving Psoriasis Area and Severity Index (PASI) 100 and cumulative treatment benefit over time in patients with moderate-to-severe psoriasis receiving brodalumab or ustekinumab by prior treatment. Methods: We conducted a post hoc analysis of data from two phase 3, randomized, controlled, 52-week AMAGINE trials of brodalumab to describe patients who achieved complete clearance as measured by PASI 100 by prior treatment subgroup (naïve to systemic and biologic treatment, systemic-treated but biologic-naïve, biologic-treated without failure, and biologic-treated with failure). A competing risk model was used to assess cumulative incidence over a 52-week period with outcomes of PASI 100 or inadequate response. Cumulative clinical benefit of treatment was determined with an area under the curve analysis. Results: The 52-week cumulative incidence of patients achieving PASI 100 was consistently higher for brodalumab vs. ustekinumab across treatment pathway subgroups (76% vs. 58% in systemic/biologic-naïve patients, 78% vs. 55% in systemic-treated/biologic-naïve patients, 75% vs. 41% in biologic-treated patients without failure, and 70% vs. 30% in biologic-treated patients with failure). Rates of inadequate response were lower with brodalumab compared with ustekinumab across all subgroups. Cumulative treatment benefit was also higher for all subgroups treated with brodalumab compared with those treated with ustekinumab. Conclusion: Treatment with brodalumab was associated with higher levels of complete clearance and greater cumulative benefit over time compared with ustekinumab, in patients with moderate-to-severe psoriasis, regardless of prior treatment experience.
Nota:	Altres ajuts: Amgen; AstraZeneca.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Humans ; Psoriasis ; Severity of Illness Index ; Treatment Outcome ; Ustekinumab
Publicat a:	Journal of the European Academy of Dermatology and Venereology, Vol. 35 Núm. 10 (october 2021) , p. 2034-2044, ISSN 1468-3083

DOI: 10.1111/jdv.17433
PMID: 34076919

11 p, 528.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats